Systemic lupus erythematosus: Cutaneous/articular involvement;Lúpus eritematoso sistêmico: Acometimento cutâneo/ articular

Revista da Associacao Medica Brasileira

Volumn 52, Issue 6, 2006, Pages 384-386

  Sato, E I ^a   Bonfa E D ^a   Costallat, L T L ^a   Silva, N A ^a   Brenol, J C T ^a   Santiago, M B ^a   Szajubok, J C M ^a   Rachid Filho, A ^a   Barros, R T ^a   Vasconcelos, M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; GLUCOCORTICOID;

EVIDENCE BASED MEDICINE; HUMAN; PRACTICE GUIDELINE; SHORT SURVEY; SKIN LUPUS ERYTHEMATOSUS; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANTIMALARIALS; EVIDENCE-BASED MEDICINE; GLUCOCORTICOIDS; HUMANS; LUPUS ERYTHEMATOSUS, CUTANEOUS; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 33846830048     PISSN: 01044230     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0104-42302006000600012     Document Type: Short Survey

References (25)

1. Rus V, Hochberg MC. The epidemiology of systemic lupus erythematosus. In: Wallace DJ, Hahn BH, editors. Dubois lupus erythematosus. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2002. p.66-83.
2. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271-7.
3. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.
4. Dellavance A, Gabriel-Jr A, Cintra AF, Ximenes AC, Nuccitelli B, von Mühlen CA. I Consenso Nacional para Padronização dos Laudos de FAN HEp-2. J Bras Patol Med Lab. 2002;38:207-16.
5. Wallace DJ. Principles of therapy and local measures. In: Wallace DJ, Hahn BH, editors. Dubois lupus erythematosus. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2002. p.1131-47.
6. Meinao IM, Sato EI, Andrade LE, Ferraz MB, Atra E. Controlled trial with chloroquine diphosphate in systemic lupus erythematosus. Lupus. 1996;5:237-41.
7. The Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med. 1991;324:150-4.
8. Petri M, Lakatta C, Magder L, Goldman D. Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis. Am J Med. 1994;96:254-9.
9. Borba EF, Bonfa E. Long term beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy. J Rheumatol. 2001; 28:780-5.
10. Wallace DJ, Linker-Israeli M, Metzger AL, Stecher VJ. The relevance of antimalarial therapy with regard to thrombosis, hypercholesterolemia and cytokines in SLE. Lupus. 1993;2(Suppl 1):S13-5.
11. th ed. Philadelphia: Lippincott Williams & Wilkins; 2002. p.1173-94.
12. Boumpas DT, Chrousos GP, Wilder RL, Cupps TR, Balow JE. Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann Intern Med. 1993;119:1198-208.
13. Maccune WJ, Riskalla M. Immunossuppressive drug therapy. In: Wallace DJ, Hahn BH, editors. Dubois lupus erythematosus. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2002. p.1195-217.
14. Carneiro JR, Sato EI. Double blind, randomized, placebo controlled clinical trial of methotrexate in systemic lupus erythematosus. J Rheumatol. 1999;26:1275-9.
15. Walchner M, Messer G, Kind P. Phototesting and photoprotection in LE. Lupus. 1997;6:167-74.
16. Vila LM, Mayor AM, Valentin AH, Rodriguez SI, Reyes ML, Acosta E, et al. Association of sunlight exposure and photoprotection measures with clinical outcome in systemic lupus erythematosus. P R Health Sci J 1999;18:89-94.
17. Maggio KL, Singer MT, James WD. Clinical pearl: discoid lupus erythematosus - treatment with occlusive compression. J Am Acad Dermatol 1996;35:627-8.
18. Costner MI, Sontheimer RD, Provost TT. Lupus erythematosus. In: Sontheimer RD, Provost TT, editors. Cutaneous manifestations of rheumatic diseases. Philadelphia: Lippincott Williams & Wilkins; 2003. p.15-64.
19. Atra E, Sato EI. Treatment of the cutaneous lesions of systemic lupus erythematosus with thalidomide. Clin Exp Rheumatol. 1993;11:487-93.
20. Callen JP, Spencer LV, Burruss JB, Holtman J. Azathioprine: an effective, corticosteroid-sparing therapy for patients with recalcitrant cutaneous lupus erythematosus or with recalcitrant cutaneous leukocytoclastic vasculitis. Arch Dermatol. 1991;127:515-22.
21. Mackey JP, Barnes J. Clofazimine in the treatment of discoid lupus erythematosus. Br J Dermatol. 1974;91:93-6.
22. Hall RP, Lawley TJ, Smith HR, Katz SI. Bullous eruption of systemic lupus erythematosus: dramatic response to dapsone therapy. Ann Intern Med. 1982;97:165-70.
23. Yousefi K, Weisman MH. Salicylate and nonsteroidal therapy. In: Wallace DJ, Hahn BH, editors. Dubois lupus erythematosus. 6th Philadelphia: Lippincott Williams & Wilkins; 2002. p.1141-7.
24. Williams HJ, Egger MJ, Singer JZ, Willkens RF, Kalunian KC, Clegg DO, et al. Comparison of hydroxychloroquine and placebo in the treatment of the arthropathy of mild systemic lupus erythematosus. J Rheumatol. 1994;21:1457-62.
25. Rahman P, Humphrey-Murto S, Gladman DD, Urowitz MB. Efficacy and tolerability of methotrexate in antimalarial resistant lupus arthritis. J Rheumatol. 1998;25:243-6.